Pfizer Won't Get To Trim BYU's Bextra-Celebrex Suit

Law360, New York (March 13, 2012, 7:34 PM EDT) -- A Utah federal judge on Tuesday declined to rule on two claims in a contract and trade secrets suit brought against Pfizer Inc. by Brigham Young University and a professor who claims he discovered an enzyme that led to the development of the anti-inflammatory drugs Bextra and Celebrex.

Pfizer had asked the court to grant summary judgment on BYU's claims that Pfizer breached two parts of a research agreement originally signed by the University and co-defendant Monsanto Co., the pharmaceutical wing of which is now under...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.